PMID- 22085127 OWN - NLM STAT- MEDLINE DCOM- 20111230 LR - 20220331 IS - 1464-410X (Electronic) IS - 1464-4096 (Linking) VI - 108 Suppl 2 DP - 2011 Nov TI - A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. PG - 45-50 LID - 10.1111/j.1464-410X.2011.10686.x [doi] AB - What's known on the subject? and What does the study add? There is controversy over the use of anti-platelet and anti-coagulant drugs in men undergoing TURP with contradictory evidence on the effect of the drugs on bleeding following the operation, particularly for aspirin. If anti-platelet or anti-coagulant drugs are not stopped for TURP, there is an unacceptable burden of bleeding. If the drugs are stopped there is an unacceptable rate of cardiovascular events. OBJECTIVE: * To determine the morbidity associated with perioperative management of antiplatelet (AP) or anticoagulant (AC) medication and transurethral prostatectomy. PATIENTS AND METHODS: * A retrospective review was performed on 163 consecutive patients undergoing transurethural prostatectomy. * Patients were grouped according to the perioperative management of AP and AC medications: control patients not prescribed any AP/AC drugs (group 1), those on AP/AC who had ceased them perioperatively (group 2) and those whose AP/AC were continued (group 3). * Warfarin was withheld perioperatively for all patients. * Morbidity associated with increased blood loss and cardiovascular or cerebrovascular events was recorded and differences were analysed with SPSS version 16 software. RESULTS: * There was a statistically significant increase in bleeding-associated morbidity in group 2 (13/65) and group 3 (6/7) compared with the controls (9/91) (P < 0.01). * Cardiovascular and cerebrovascular events were only seen in group 2 (6/65), statistically significantly higher than the event rate in the other groups (P